(Reuters) – Swiss drugmaker Novartis (NOVN.VX) is digging deeper into cancer immunotherapy, one of the hottest areas of drug research, through a tie-up with Aduro Biotech (ADRO.O) worth up to $750 million. The move comes as the privately owned California-based b…
Source: Novartis digs deeper into cancer with up to $750 million Aduro deal
Monday, March 30, 2015
Novartis digs deeper into cancer with up to $750 million Aduro deal
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment